Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) has completed a non-brokered private placement, issuing 5,318,183 units at $0.22 per unit, yielding approximately $1,170,000. Each unit includes a common share and a common share purchase warrant, allowing warrant holders to acquire an additional common share at $0.28 within 5 years. The funds raised will support the ongoing Phase II clinical study for Non-Muscle Invasive Bladder Cancer and address working capital requirements in Theralase's pursuit of innovative cancer, bacteria, and virus treatment developments.
The Markets by Proactive
Go to Proactive UK
Proactive’s coverage of London’s small caps continues on .com